TCBWMS
ESPR

Texas Capital Bank Wealth Management Services’s Esperion Therapeutics ESPR Stock Holding History

Texas Capital Bank Wealth Management Services’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-10,000
Closed -$16.5K – 180
2024
Q3 		$16.5K Hold
10,000
– – ﹤0.01% 202
2024
Q2 		$22.2K Buy
+10,000
New +$23.5K ﹤0.01% 197

Other funds holding ESPR

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Texas Capital Bank Wealth Management Services's ESPR Position: Q4 2024 in Review

Texas Capital Bank Wealth Management Services sold out of Esperion Therapeutics (ESPR) in Q4 2024, closing a stake of 10,000 shares — an estimated $16.5K sold.

Texas Capital Bank Wealth Management Services first reported a position in ESPR in Q2 2024 and held it in 2 quarters. The position peaked at $22.2K in Q2 2024. 189 funds tracked by Wall St. Rank hold ESPR as of Q4 2024.

  • Texas Capital Bank Wealth Management Services reported no remaining Esperion Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Texas Capital Bank Wealth Management Services sold 10,000 Esperion Therapeutics shares in Q4 2024, an estimated $16.5K.
  • Texas Capital Bank Wealth Management Services first reported a position in Esperion Therapeutics in Q2 2024 and held it in 2 quarters.
  • Texas Capital Bank Wealth Management Services's Esperion Therapeutics position peaked at $22.2K in Q2 2024.
  • 189 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q4 2024.

Based on Texas Capital Bank Wealth Management Services's 13F filing for Q4 2024, filed 13 Feb 2025.